메뉴 건너뛰기




Volumn 372, Issue 9641, 2008, Pages 807-816

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial

(820)  Fox, Kim a   Ford, Ian b   Steg, P Gabriel c   Tendera, Michal d   Ferrari, Roberto e   Grancelli, H f   Freedman, B f   Eber, B f   Vanoverschelde, J L f   Finkov, B f   Yotov, Y f   Tardif, J C f   Hu, D f   Lau, C f   Hradec, J f   Hildebrandt, P f   Eha, J f   Peuhkurinen, K f   Danchin, N f   Meinertz, T f   more..

f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; NITRATE; PLACEBO;

EID: 50649109186     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61170-8     Document Type: Article
Times cited : (970)

References (29)
  • 1
    • 32544450827 scopus 로고    scopus 로고
    • Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study
    • Daly C.A., De Stavola B., Sendon J.L., et al. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study. BMJ 332 (2006) 262-267
    • (2006) BMJ , vol.332 , pp. 262-267
    • Daly, C.A.1    De Stavola, B.2    Sendon, J.L.3
  • 2
    • 33947533514 scopus 로고    scopus 로고
    • One-year cardiovascular event rates in outpatients with atherothrombosis
    • Steg P.G., Bhatt D.L., Wilson P.W., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
    • (2007) JAMA , vol.297 , pp. 1197-1206
    • Steg, P.G.1    Bhatt, D.L.2    Wilson, P.W.3
  • 3
    • 0037005820 scopus 로고    scopus 로고
    • The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis
    • Burns R.J., Gibbons R.J., Yi Q., et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39 (2002) 30-36
    • (2002) J Am Coll Cardiol , vol.39 , pp. 30-36
    • Burns, R.J.1    Gibbons, R.J.2    Yi, Q.3
  • 4
    • 0041356972 scopus 로고    scopus 로고
    • Natural history of asymptomatic left ventricular systolic dysfunction in the community
    • Wang T.J., Evans J.C., Benjamin E.J., Levy D., LeRoy E.C., and Vasan R.S. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003) 977-982
    • (2003) Circulation , vol.108 , pp. 977-982
    • Wang, T.J.1    Evans, J.C.2    Benjamin, E.J.3    Levy, D.4    LeRoy, E.C.5    Vasan, R.S.6
  • 6
    • 34548032376 scopus 로고    scopus 로고
    • Resting heart rate in cardiovascular disease
    • Fox K., Borer J.S., Camm A.J., et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50 (2007) 823-830
    • (2007) J Am Coll Cardiol , vol.50 , pp. 823-830
    • Fox, K.1    Borer, J.S.2    Camm, A.J.3
  • 7
    • 35148892823 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice: executive summary
    • Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
    • (2007) Eur Heart J , vol.28 , pp. 2375-2414
    • Graham, I.1    Atar, D.2    Borch-Johnsen, K.3
  • 8
    • 12344330346 scopus 로고    scopus 로고
    • Elevated heart rate: A major risk factor for cardiovascular disease
    • Palatini P., and Julius S. Elevated heart rate: A major risk factor for cardiovascular disease. Clin Exp Hypertens 26 (2004) 637-644
    • (2004) Clin Exp Hypertens , vol.26 , pp. 637-644
    • Palatini, P.1    Julius, S.2
  • 9
    • 18844368814 scopus 로고    scopus 로고
    • Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
    • Diaz A., Bourassa M.G., Guertin M.C., and Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26 (2005) 967-974
    • (2005) Eur Heart J , vol.26 , pp. 967-974
    • Diaz, A.1    Bourassa, M.G.2    Guertin, M.C.3    Tardif, J.C.4
  • 10
    • 44449129008 scopus 로고    scopus 로고
    • Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST)
    • Kolloch R., Legler U.F., Champion A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29 (2008) 1327-1334
    • (2008) Eur Heart J , vol.29 , pp. 1327-1334
    • Kolloch, R.1    Legler, U.F.2    Champion, A.3
  • 11
    • 4544344025 scopus 로고    scopus 로고
    • Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease
    • DiFrancesco D., and Camm A.J. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 64 (2004) 1757-1765
    • (2004) Drugs , vol.64 , pp. 1757-1765
    • DiFrancesco, D.1    Camm, A.J.2
  • 12
    • 33644913956 scopus 로고    scopus 로고
    • Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise
    • Joannides R., Moore N., Iacob M., et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 61 (2006) 127-137
    • (2006) Br J Clin Pharmacol , vol.61 , pp. 127-137
    • Joannides, R.1    Moore, N.2    Iacob, M.3
  • 13
    • 0344394916 scopus 로고    scopus 로고
    • A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction
    • Manz M., Reuter M., Lauck G., Omran H., and Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100 (2003) 149-155
    • (2003) Cardiology , vol.100 , pp. 149-155
    • Manz, M.1    Reuter, M.2    Lauck, G.3    Omran, H.4    Jung, W.5
  • 14
    • 0042357093 scopus 로고    scopus 로고
    • Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology
    • Camm A.J., and Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4 (2003) 83-89
    • (2003) Drugs R D , vol.4 , pp. 83-89
    • Camm, A.J.1    Lau, C.P.2
  • 15
    • 0037448788 scopus 로고    scopus 로고
    • Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial
    • Borer J.S., Fox K., Jaillon P., and Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 (2003) 817-823
    • (2003) Circulation , vol.107 , pp. 817-823
    • Borer, J.S.1    Fox, K.2    Jaillon, P.3    Lerebours, G.4
  • 16
    • 27944492366 scopus 로고    scopus 로고
    • Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina
    • Tardif J.C., Ford I., Tendera M., Bourassa M.G., and Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26 (2005) 2529-2536
    • (2005) Eur Heart J , vol.26 , pp. 2529-2536
    • Tardif, J.C.1    Ford, I.2    Tendera, M.3    Bourassa, M.G.4    Fox, K.5
  • 17
    • 33748781606 scopus 로고    scopus 로고
    • Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study
    • Fox K., Ferrari R., Tendera M., Steg P.G., and Ford I. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular dysfunction: the morBidity-mortality EvAlUation of the If inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) Study. Am Heart J 152 (2006) 860-866
    • (2006) Am Heart J , vol.152 , pp. 860-866
    • Fox, K.1    Ferrari, R.2    Tendera, M.3    Steg, P.G.4    Ford, I.5
  • 18
    • 46349083598 scopus 로고    scopus 로고
    • The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population
    • The BEAUTIFUL Study Group
    • The BEAUTIFUL Study Group. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology 110 (2008) 271-282
    • (2008) Cardiology , vol.110 , pp. 271-282
  • 19
    • 0042330455 scopus 로고    scopus 로고
    • Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    • EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
    • Fox K.M., and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
    • (2003) Lancet , vol.362 , pp. 782-788
    • Fox, K.M.1
  • 20
    • 13544262459 scopus 로고    scopus 로고
    • Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial
    • McMurray J., Kober L., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
    • (2005) J Am Coll Cardiol , vol.45 , pp. 525-530
    • McMurray, J.1    Kober, L.2    Robertson, M.3
  • 21
    • 0037070736 scopus 로고    scopus 로고
    • Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial
    • IONA Study Group
    • IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 359 (2002) 1269-1275
    • (2002) Lancet , vol.359 , pp. 1269-1275
  • 22
    • 0017042882 scopus 로고
    • Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
    • Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34 (1976) 585-612
    • (1976) Br J Cancer , vol.34 , pp. 585-612
    • Peto, R.1    Pike, M.C.2    Armitage, P.3
  • 23
    • 34247113737 scopus 로고    scopus 로고
    • Optimal medical therapy with or without PCI for stable coronary disease
    • Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
    • (2007) N Engl J Med , vol.356 , pp. 1503-1516
    • Boden, W.E.1    O'Rourke, R.A.2    Teo, K.K.3
  • 24
    • 0344806945 scopus 로고    scopus 로고
    • The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment
    • Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003) 464-474
    • (2003) Eur Heart J , vol.24 , pp. 464-474
    • Komajda, M.1    Follath, F.2    Swedberg, K.3
  • 26
    • 0035949564 scopus 로고    scopus 로고
    • Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption
    • Heidland U.E., and Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104 (2001) 1477-1482
    • (2001) Circulation , vol.104 , pp. 1477-1482
    • Heidland, U.E.1    Strauer, B.E.2
  • 27
    • 0033549290 scopus 로고    scopus 로고
    • Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
    • Hjalmarson A., Goldstein S., Fagerberg B., et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
    • (1999) Lancet , vol.353 , pp. 2001-2007
    • Hjalmarson, A.1    Goldstein, S.2    Fagerberg, B.3
  • 28
    • 0033514046 scopus 로고    scopus 로고
    • The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
    • Dargie H.J., Lechat P., Erdmann E., et al. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
    • (1999) Lancet , vol.353 , pp. 9-13
    • Dargie, H.J.1    Lechat, P.2    Erdmann, E.3
  • 29
    • 0035978763 scopus 로고    scopus 로고
    • Effect of carvedilol on survival in severe chronic heart failure
    • Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
    • (2001) N Engl J Med , vol.344 , pp. 1651-1658
    • Packer, M.1    Coats, A.J.2    Fowler, M.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.